US20040058359A1 - Erbin as a negative regulator of Ras-Raf-Erk signaling - Google Patents

Erbin as a negative regulator of Ras-Raf-Erk signaling Download PDF

Info

Publication number
US20040058359A1
US20040058359A1 US10/446,640 US44664003A US2004058359A1 US 20040058359 A1 US20040058359 A1 US 20040058359A1 US 44664003 A US44664003 A US 44664003A US 2004058359 A1 US2004058359 A1 US 2004058359A1
Authority
US
United States
Prior art keywords
erbin
cells
ras
raf
erk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/446,640
Inventor
Lin Mei
Wem Xiong
Yang Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
Lin Mei
Xiong Wem C.
Huang Yang Z.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Mei, Xiong Wem C., Huang Yang Z. filed Critical Lin Mei
Priority to US10/446,640 priority Critical patent/US20040058359A1/en
Publication of US20040058359A1 publication Critical patent/US20040058359A1/en
Assigned to THE UAB RESEARCH FOUNDATION reassignment THE UAB RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: XIONG, WEN C., HUANG, YANGZHONG, MEI, LIN
Abandoned legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/67—Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components ; Apparatus not specifically provided for elsewhere
    • H01L21/67005—Apparatus not specifically provided for elsewhere
    • H01L21/67242—Apparatus for monitoring, sorting or marking
    • H01L21/67253—Process monitoring, e.g. flow or thickness monitoring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
    • C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
    • C23C16/4401—Means for minimising impurities, e.g. dust, moisture or residual gas, in the reaction chamber
    • C23C16/4404—Coatings or surface treatment on the inside of the reaction chamber or on parts thereof
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
    • C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
    • C23C16/52—Controlling or regulating the coating process
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J37/00—Discharge tubes with provision for introducing objects or material to be exposed to the discharge, e.g. for the purpose of examination or processing thereof
    • H01J37/32—Gas-filled discharge tubes
    • H01J37/32917—Plasma diagnostics
    • H01J37/32935—Monitoring and controlling tubes by information coming from the object and/or discharge
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/67—Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components ; Apparatus not specifically provided for elsewhere
    • H01L21/67005—Apparatus not specifically provided for elsewhere
    • H01L21/67011—Apparatus for manufacture or treatment
    • H01L21/67017—Apparatus for fluid treatment
    • H01L21/67063—Apparatus for fluid treatment for etching
    • H01L21/67069—Apparatus for fluid treatment for etching for drying etching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Definitions

  • This invention relates to use of Erbin as a novel suppressor of Ras for inhibition of cell, particularly malignant cell, proliferation.
  • Erbin has now been found to be a negative regulator of the Ras-Raf-Erk signaling pathway.
  • Extracellular signal regulated kinases are a subfamily of mitogen-activated protein kinases (MAPK) that play important roles in a great array of cell programs, including proliferation, differentiation and apoptosis.
  • MAPK mitogen-activated protein kinases
  • receptor typrosine kinases are activated and undergo autophophorylation on tyrosine residues.
  • the phosphorylated tyrosine residues recruit adaptor proteins to plasma membrane by directly interacting with modules including Sre homology 2 (SH2) or phosphotyrosine binding domain (PTB).
  • SH2 Sre homology 2
  • PTB phosphotyrosine binding domain
  • Grb2 one such adaptor, brings guanyl nucleotide exchange factor (SOS) to the plasma membrane in proximity with Ras and expedites exchange of GDP and GTP on Ras.
  • SOS guanyl nucleotide exchange factor
  • the activated Ras (GTP-bound) then directly binds to Raf and allows the latter to be activated at the plasma membrane.
  • Active Raf triggers sequential activation of MEK, a MAPK kinase, and Erk, leading to phosphorylation of various regulatory proteins, including nuclear transcription factors such as Erk-1 and Myc as well as many cytoplasmic proteins.
  • Ras-Raf-Erk pathway Several modulators have been identified that positively influence the pathway at different levels.
  • MEK partner 1 MP1
  • MP1 MEK partner 1
  • a second protein is the Kinase Suppresor of Ras (KSR) that is believed to act as a scaffold for Raf-1, MEK and Erk instead of a Raf kinase although it contains a kinase domain.
  • KSR Kinase Suppresor of Ras
  • a third such regulator is the Connector Enhancer of KSR (CNK) with multiple functional domains that directly binds to Raf and is involved in activation of the Raf/MEK/Erk pathway.
  • CNK Connector Enhancer of KSR
  • Sur-8 Another interesting protein is Sur-8 that contains multiple leucine-rich regions (LRR) and binds to both Ras and Raf-1. Although Ras can directly associate with Raf when it is activated by charging with GTP, the presence of Sur8 increases the interaction between Ras and Raf and the activation of downstream signaling events. These non-enzymatic factors are important regulators for normal cell proliferation and differentiation.
  • Ras pathway there are negative regulators of the Ras pathway in cells.
  • Sprouty a Ras suppressor in Drosophila and its mammalian homologue Spred (Sprouty-related EVH1 domain-containing protein) appear to serve as physiological negative feedback regulators of growth factor-mediated Erk pathway.
  • the Ras effector RINI has been shown to inhibit Ras-induced activation of Raf by competitively binding to active Ras.
  • the Raf kinase inhibitory protein (RKIP) initially isolated as a phosphatidylethanolamine binding protein, binds directly to the kinase domains of both Raf and MEK and inhibits MEK phosphorylation.
  • These negative regulators function to ensure that all programs are adequately executed through autonomous turn-on and turn-off mechanisms. They may also counterbalance over-amplified proliferative signals caused by active mutation of Ras frequently occurring in human cancers or mutation of upstream components leading to the increased activity of the wild-type Ras which is found as well in human cancers. Such an inhibitory mechanism is key to maintain normal cell growth rate.
  • Erbin belongs to the LAP (LRR and PDZ) protein family of PDZ domain-containing proteins.
  • the family members include LET-413 in C. elegans, Scribble, a Drosophila protein essential for epithelial integrity, Densin-180, and Lano in mammals. Genetic studies in non-vertebrate have demonstrated that LAP proteins play a role in cell polarity and cell morphology of epithelial cells.
  • Erbin was initially identified as a binding partner for ErbB2 and delta-catenin and ARVCF. This 180-kDa protein contains two domains: LRR and PDZ.
  • the sequence of Erbin has been deposited in GenBank and assigned No. AF 263744. The biological function of Erbin and its impact on ErbB2-mediated signaling have yet to be addressed.
  • the instant invention provides a method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.
  • the amount of DNA administered is sufficient to provide a blood concentration of 1 ⁇ M to 100 ⁇ M of DNA which encodes Erbin into the cells.
  • the DNA encoding Erbin may be administered via viral vectors.
  • the invention also provides methods for evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue.
  • This invention relates to use of Erbin, a known protein whose sequence is known and a DNA sequence encoding Erbin is deposited in GenBank as No. AF 263744, which is: aaagatcttt tttttttttttttttttttttttttttggcgga gatcctcgtt (SEQ ID. No.
  • Erbin is a negative regulator of the Ras-Raf-Erk signaling pathway. Expression of Erbin decreases neuregulin-induced transcription of AChR ⁇ -subunit gene, an event that requires Erk activation. Although it interacts with the ErbB2 C-terminus through the PDZ domain, Erbin has no effect on ErbB2 tyrosine phosphorylation and binding to adaptor proteins Shc or Grb2. In contrast, expression of Erbin greatly impairs Erk activation by ligands that activate receptor tyrosine kinases, without causing a significant change in AKT activity. It is now shown herein that Erbin diminishes the ability of Ras but not Raf-1 to activate Erk.
  • Erbin binds only to active Ras, as opposed to inactive Ras or Raf, resulting in inhibition of the interaction between Ras and Raf both in vivo and in vitro.
  • Erbin acts to suppress tumorigenesis of cancer cells, especially breast and prostate cancer cells.
  • the control of tumorigenesis by increasing level of Erbin in malignant tissue by various means, especially through gene therapy, to obtain a blood or target tissue cell concentration of about 1 ⁇ M to 100 ⁇ M concentration would be appropriate for control of malignancies.
  • Plasmid Construction The human Erbin N-terminal domain (aa 1-391) consisting of 16 LRRs was generated by PCR amplification using sense primer containing BamHI and antisense primer containing XhoI. The resulting 1.2 kb-fragment was digested with BamHI and XhoI, and subcloned in the BamHI-SalI sites of yeast vector pGBT9 downstream of the Gal4 DNA binding domain (Clontech). Myc-Erbin LRR, Myc-ErbinD965 and Myc-DPDZ were generated by introducing a stop codon after the LRR domain following aa 965 or aa 1279 in pRK5-Myc-Erbin.
  • N-terminal deletion mutant (pRK5-Erbin965) was described previously (Huang, Y. Z., Wang, Q., Xiong, W. C., and Mei, L. (2001) J Biol Chem 276, 19318-19326); and Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Sydney, J., Margolis, B., and Birnbaum, D. (2000) Nat Cell Biol 2, 407-414).
  • pCMV-Flag-Erk1 was generously provided by Dr. Mike Weber (University of Virginia).
  • Flag-Ras, Flag-RasV12, Flag-RasN17, GST-Raf-C4, and GST-Raf-BXB were described as previously (Zang, M., Hayne, C., and Luo, Z. (2002) J Biol Chem 277, 4395-4405).
  • HEK 293 cells and COS-7 cells were cultured as described previously (Huang, supra).
  • the C2C2 cells were maintained as undifferentiated myoblasts in DMEM with high glucose supplemented with 20% fetal bovine serum, and 0.5% chicken embryo extract. Fusing of myoblasts into myotubes was induced by culturing myoblasts for 48 hours in differentiation medium DM (DMEM plus 4% horse serum).
  • DMEM fetal bovine serum
  • Rat lung epithelial Mv1Lu cells were maintained in DMEM plus 10% fetal bovine serum (FBS).
  • Rat pheochromocytoma-derived PC12 cells were grown in DMEM supplemented with 10% FBS and 5% horse serum.
  • HEK 293, COS-1 and C2C12 cells were transfected with the standard calcium phosphate technique.
  • PC12 cells and Mv1Lu cells were transfected with SuperFect regents (Qiagen).
  • Two days after transfection cells were washed with PBS and lysed in the modified RIPA buffer containing 20 mM sodium phosphate, pH 7.4, 50 mM sodium fluoride, 40 mM sodium pyrophosphate, 1% Triton X-100, 2 mM sodium vanadate, 10 mM p-nitrophenyl phosphate, and protease inhibitors. Lysed cells were incubated on ice for 20 min and centrifuged at 13,000 ⁇ g for 10 min at 4 C. The clear supernatant was designated as cell lysates.
  • Immunoprecipitation and Immunoblottina Cell lysates ( ⁇ 400 ⁇ g of protein) were incubated without or with indicated antibodies one hour at 40° C. and subsequently with protein A- or protein G-agarose beads overnight at 4° C. on a rotating platform. After centrifugation, beads were washed five times with the modified RIPA buffer. Bound proteins were eluted with the SDS sample buffer, resolved by SDS-PAGE and transferred onto nitrocellulose membranes (Schleicher and Schuell).
  • Nitrocellulose membranes were incubated at room temperature for one hour in the blocking buffer containing Tris-buffered saline with 0.1% Tween (TBS-T) containing 5% milk or 5% BSA followed by an incubation with indicated antibodies in the blocking buffer. After washing 3 times for 5 min each with TBS-T, the membrane was incubated with horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit IgG (Amersham Pharmacia Biotech) followed by washing. Immunoreactive bands were visualized with enhanced chemiluminescence substrate (Pierce).
  • the nitrocellulose filter was incubated in a buffer containing 62.5 mM Tris/HCl, pH 6.7, 100 mM ⁇ -mer-captoenthanol, and 2% SDS at 50° C. for 30 min, and washed with 0.1% Tween 20 in 50 mM TBS at room temperature for 1 hr, and reblotted with different antibodies.
  • the following antibodies were used: Flag (M2, Sigma), Myc (9E10, Santa Cruz), phospho-MAPK (Promega), phospho-Akt (Ser473, New England Biolab) and Erbin.
  • Luciferase Assay Myoblasts were co-transfected with or without Myc-Erbin, plus the ⁇ -subunit promoter-luciferase transgene that contains 416 nucleotides of the 5′UTR of the ⁇ -subunit gene (25) and a control plasmid pRL-SV40 (Promega). Twenty four hours after transfection, the myoblasts were incubated in DM to induce myotube formation. Myotube formation was complete 48 hours after switch to DM. The C2C12 myotubes were stimulated with neuregulin at a final concentration of 10 Nm at 37° C. for 24 hours.
  • Mv1Lu cells were transiently transfected with the promoter reporter construct p3TP-Lux, which promoter contains three AP-1 sites and the plasminogen activator inhibitor-1 (PAI-1) promoter and firefly luciferase.
  • pRL-SV40 that express Renilla luciferase under the control of SV40 promoter was cotransfected as a control to monitor the transfection efficiency.
  • Fourty eight hours after transfection cells were lysed and activities of the two different luciferases were assayed with respective substrates with a dual luciferase assay kit (Promega).
  • PC12 cells were cotransfected pEGFP with empty vector pRK5-Myc, Myc-Erbin or its mutants, or Erbin RNAi duplex. Forty eight hours after transfection, PC12 cells were stimulated by 100 ng/ml or 20 ⁇ g/ml NGF for 2 days. Cells were examined by fluorescence microscopy. Cells with processes 1.5 times longer than the diameter of the cell body were considered to be differentiated.
  • RNAi Inhibition of Erbin expression by RNAi—The target region of siRNA was 100 nt downstream of the start codon, which contained approximately 50% G/C content.
  • the nucleotide sequence was 5′ UAG ACU GAC CCA GCU GGA A dTdT 3′ (nt 866-884) (Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Sydney, J., Margolis, B., and Birnbaum, D. (2000) Nat Cell Biol 2, 407-414).
  • the NCBI sequence bank was searched against this segment Cof DNA using the blast program, which revealed no match, suggesting of the specificity of target recognition by siRNA.
  • the 21-nucleotide RNAs were chemically synthesized by Dharmacon Research Inc. Synthetic oligonucleotides were deprotected and gel-purified.
  • To demonstrate the silencing effect of endogenous Erbin expression by siRNA cells in 60 mm-culture dish were co-transfected with empty vector pEGFP and with siRNA duplex using the SuperFect kit (Qiagen). Briefly, 2 mg of pEGFP and 30 ml of 20 mM RNAi duplex were mixed with 300 ml of Opti-MEM (GIBCO-BRL).
  • Opti-MEM was added to obtain a final volume of 1 ml.
  • Cells were incubated with the mixture for 2-3 hours at 37° C. and 5% CO before the addition of 5 ml of growth medium. Seventy two hours after transfection, cells were resuspended in PBS buffer.
  • GFP-positive cells were collected by fluorescence-activated cell sorting (FACS) analysis. Cells were lysed in modified RIPA buffer and lysates were subjected to immunoblotting for expression of Erbin. In parallel experiments, GFP-positive PC12 cells were scored for differentiation.
  • Protein Assay Protein was assayed with Coomassie Protein Assay Regent (Pierce) using bovine serum albumin as a standard.
  • Erbin inhibits neuregulin-induced transcription of the AChR ⁇ -subunit gene and Erk activation—It was found that transcription of AChR subunit genes is increased by neuregulin, a ligand that activates the ErbB2 receptor tyrosine kinase. Previous studies in this laboratory and by others have demonstrated that neuregulin-induced AChR expression requires ErbB2 tyrosine phosphorylation and activation of the Ras-Raf-Erk signaling pathway. It now is seen that Erbin, interacting with ErbB2, plays a role in regulating neuregulin signaling.
  • Erbin inhibits Erk activation by Ras—An attempt was made to dissect the position for Erbin action by walking upstream of Erk. Since ErbB2 directly interacts with the cytoplasmic domain of tyrosine kinase receptors, it is possible that Erbin interferes with the tyrosine kinase activation and/or subsequent binding to adaptor proteins. To test these hypotheses, it was decided to take the advantage of NeuT, an active form of ErbB2 (Bargmann, C. I., Hung, M. C., and Weinberg, R. A. (1986) Cell 45, 649-657).
  • Erbin disrupts the Ras-Raf interaction—In considering the mechanism of the Erbin-induced inhibition of the Erk pathway, it was postulated that Erbin inhibits the interaction between active Ras and Raf by competitive binding to either of them, or diminishing the GTP-bound form of Ras. To test this, an active mutant of Ras (Flag-RasV12) was coexpressed with GST-Raf1 into HEK293 cell. Flag-RasV12 was found to copurify with GST-Raf1. In a reciprocal study, Raf1 was detected in the immunoprecipitates of active Ras. Remarkably, coexpression of Erbin decreased the interaction between active Ras and Raf.
  • the Ras pull-down assay developed by Rooij and Bos in which they exploited the nature of high affinity of GTP-Ras for the Ras-binding domain (RBD) of Raf-1, as compared with GDP-Ras was employed.
  • the RBD (aa 50-150) was expressed as a GST-fusion protein and used to pull down GTP-Ras that had been activated inside cells cotransfected with or without Erbin.
  • GTP-Ras was recovered by the GST-Raf-RBD beads.
  • Expression of Erbin inhibited the interaction of Raf with growth factor-activated Ras, accompanied by a decrease in phospho-Erk1.
  • RNA interference (RNAi) techniques were used for this purpose.
  • sequence-specific double-stranded RNA are first employed in evolutionarily diverse organisms including plants, fungi, and metazoans (Hammond, S. M., Caudy, A. A., and Hannon, G. J. (2001) Nat Rev Genet 2, 110-119).
  • RNAi has been shown to specifically suppress the expression of endogenous and heterologous genes in mammalian cell lines.
  • RNAi duplexes directed against Erbin were synthesized and transfected in PC12 cells to suppress the expression of endogenous Erbin.
  • cells expressing co-transfected EGFP were sorted out and analyzed for Erbin expression by Western blot.
  • Expression of Erbin in RNAi-transfected cells was significantly decreased in comparison with missense RNAi-transfected cells (control).
  • the suppressing effect by Erbin RNAi appeared to be specific since it had no effect on expression of endogenous Erk1.
  • expression of cotransfected EGFP was unaffected.
  • RNAi-transfected PC12 cells were challenged with 20 ng/ml NGF to induce differentiation.
  • NGF a sub-maximal effective concentration of NGF was used, as at this concentration, NGF caused differentiation of only 25 ⁇ 2% PC12 cells.
  • suppressing Erbin expression by sense RNAi enhanced NGF-mediated cell differentiation (52 ⁇ 2%), while missense RNAi had no significant effect (18 ⁇ 2%).
  • Ad-Erbin or Erbin-LRR and control AdGFP adenoviruses are generated in BJ5183 (available from American Type Culture Collection (ATCC) as deposit JHU-18) bacterial cells by homologous recimbination of the viral pAdEasy-1 and pAdTrack CMV-Erbin or Erbin-LRR and pAdTrack-CMV, respectively.
  • ATCC American Type Culture Collection
  • Cells available from ATCC under deposit number CRL-1573 known as 293 cells are used as hosts for viral productions by known methods. (See Neuron. (2002), 35:489-505)
  • the adenoviruses expressing Erbin or Erbin-LRR are injected into the tumor tissue to infect cancer cells, particularly breast or prostate cancer cells.
  • mice are anesthetized with phenobarbital sodium.
  • Tumor tissues are injected with 100 ⁇ g of closed circular DNA (pcDNA3-Erbin or Erbin-LRR) at concentration of 1.0 ⁇ g/ ⁇ l in saline using a syringe with a 27-gauge needle.
  • injected tumor tissues are subjected to electroporation with a pair of tungsten needles inserted into the tumor encompassing DNA injection sites. Electric pulses are delivered using an electric pulse generator.
  • Erbin expression in tumor tissues and cells may be monitored by two methods: Western blot and immunohitochemical analysis, both using anti-Erbin antibody.
  • Tumor tissues are rapidly dissected and frozen in isopentane cooled with dry ice. Ten ⁇ M sections are prepared using a cryostat, thaw mounted on gelatin-coated slides and stored at ⁇ 80°C. Sections of tumor tissue sections are incubated with 2% normal goat serum (Vector Laboratories, Burlingame, Calif.) in PBS for 1 hour at room temperature to reduce background staining and then incubated with the affinity-purified and anti-Erbin antibody in 2% normal goat serum in PBS overnight at 4° C.
  • 2% normal goat serum Vector Laboratories, Burlingame, Calif.
  • the sections After wiashing the sections five times with PBS, each for 30 minutes, the sections are incubated with a flourescein istothiocyanate-conjugated anti-rabbit antibody (Zymed Laboratories Inc., San Francisco, Calif.) or visualized by the established DAB method. Fluorescent images are captured on Sony CCD camera mounted on a Nikon E600 microsope using Photoshop imaging software. The amount of Erbin is then determined.
  • a flourescein istothiocyanate-conjugated anti-rabbit antibody Zymed Laboratories Inc., San Francisco, Calif.
  • Fluorescent images are captured on Sony CCD camera mounted on a Nikon E600 microsope using Photoshop imaging software. The amount of Erbin is then determined.
  • the amount of Erbin as measured is measured against standards and against the amount of Erbin in normal tissues. It is also possible to evaluate progression of disease by measuring the amount of Erbin in samples from target tissue repeatedly.
  • Erbin functions to kick Raf off the plasma membrane by competing with Raf in binding to active Ras.
  • overexpression of Erbin diminishes the accessibility of Ras-GTP to Raf-1.
  • Erbin may compete with Sur-8 for binding to Ras and then dissociate the Sur 8/Ras/Raf ternary complex, resulting in down-regulation of the Erk pathway. It is conceivable that Erbin may act more quickly and efficiently than Sur 8, as it is enriched at the plasma membrane. Active mutations of the Ras gene renders it the most frequent oncogene found in human cancers and even more, many other oncogenes exploit Ras and its downstream cohorts to execute their functions.
  • Erbin for inhibitory mechanisms and blockers for this pathway is indicted as a means of inhibiting growth of malignant cells.
  • the method involved administration of a proliferation inhibiting effective amount of Erbin or the administration of a vector which gives rise to production of a proliferation inhibiting effective amount of Erbin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Power Engineering (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plasma & Fusion (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

The instant invention provides a method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.
The invention also provides methods for evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue.

Description

  • This application takes priority from Provisional Patent Application No. 60/383,603 filed May 29, 2003.[0001]
    • BACKGROUND AND FIELD OF THE INVENTION
  • This invention relates to use of Erbin as a novel suppressor of Ras for inhibition of cell, particularly malignant cell, proliferation. Erbin has now been found to be a negative regulator of the Ras-Raf-Erk signaling pathway. [0002]
  • Extracellular signal regulated kinases (Erk) are a subfamily of mitogen-activated protein kinases (MAPK) that play important roles in a great array of cell programs, including proliferation, differentiation and apoptosis. As exemplified by binding to growth factors such as EGF, receptor typrosine kinases are activated and undergo autophophorylation on tyrosine residues. The phosphorylated tyrosine residues recruit adaptor proteins to plasma membrane by directly interacting with modules including Sre homology 2 (SH2) or phosphotyrosine binding domain (PTB). Grb2, one such adaptor, brings guanyl nucleotide exchange factor (SOS) to the plasma membrane in proximity with Ras and expedites exchange of GDP and GTP on Ras. The activated Ras (GTP-bound) then directly binds to Raf and allows the latter to be activated at the plasma membrane. Active Raf triggers sequential activation of MEK, a MAPK kinase, and Erk, leading to phosphorylation of various regulatory proteins, including nuclear transcription factors such as Erk-1 and Myc as well as many cytoplasmic proteins. [0003]
  • In the past, extensive efforts have been made to identify factors that participate in the regulation of Ras-Raf-Erk pathway. Several modulators have been identified that positively influence the pathway at different levels. For example, MEK partner 1 (MP1) was isolated as a binding protein that interacts with both MEK1 and Erk 1 to enhance the efficiency of Erk phosphorylation by MEK. A second protein is the Kinase Suppresor of Ras (KSR) that is believed to act as a scaffold for Raf-1, MEK and Erk instead of a Raf kinase although it contains a kinase domain. A third such regulator is the Connector Enhancer of KSR (CNK) with multiple functional domains that directly binds to Raf and is involved in activation of the Raf/MEK/Erk pathway. Another interesting protein is Sur-8 that contains multiple leucine-rich regions (LRR) and binds to both Ras and Raf-1. Although Ras can directly associate with Raf when it is activated by charging with GTP, the presence of Sur8 increases the interaction between Ras and Raf and the activation of downstream signaling events. These non-enzymatic factors are important regulators for normal cell proliferation and differentiation. [0004]
  • In addition, there are negative regulators of the Ras pathway in cells. Sprouty, a Ras suppressor in Drosophila and its mammalian homologue Spred (Sprouty-related EVH1 domain-containing protein) appear to serve as physiological negative feedback regulators of growth factor-mediated Erk pathway. The Ras effector RINI has been shown to inhibit Ras-induced activation of Raf by competitively binding to active Ras. Additionally, the Raf kinase inhibitory protein (RKIP), initially isolated as a phosphatidylethanolamine binding protein, binds directly to the kinase domains of both Raf and MEK and inhibits MEK phosphorylation. These negative regulators function to ensure that all programs are adequately executed through autonomous turn-on and turn-off mechanisms. They may also counterbalance over-amplified proliferative signals caused by active mutation of Ras frequently occurring in human cancers or mutation of upstream components leading to the increased activity of the wild-type Ras which is found as well in human cancers. Such an inhibitory mechanism is key to maintain normal cell growth rate. [0005]
  • Erbin belongs to the LAP (LRR and PDZ) protein family of PDZ domain-containing proteins. In addition to Erbin, the family members include LET-413 in [0006] C. elegans, Scribble, a Drosophila protein essential for epithelial integrity, Densin-180, and Lano in mammals. Genetic studies in non-vertebrate have demonstrated that LAP proteins play a role in cell polarity and cell morphology of epithelial cells. Erbin was initially identified as a binding partner for ErbB2 and delta-catenin and ARVCF. This 180-kDa protein contains two domains: LRR and PDZ. The sequence of Erbin has been deposited in GenBank and assigned No. AF 263744. The biological function of Erbin and its impact on ErbB2-mediated signaling have yet to be addressed.
    • SUMMARY OF THE INVENTION
  • The instant invention provides a method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells. The amount of DNA administered is sufficient to provide a blood concentration of 1 μM to 100 μM of DNA which encodes Erbin into the cells. The DNA encoding Erbin may be administered via viral vectors. [0007]
  • The invention also provides methods for evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue.[0008]
    • DETAILED DESCRIPTION OF THE INVENTION
  • This invention relates to use of Erbin, a known protein whose sequence is known and a DNA sequence encoding Erbin is deposited in GenBank as No. AF 263744, which is: [0009]
    aaagatcttt tttttttttt tttctttttt tttcggcgga gatcctcgtt (SEQ ID. No. 1)
    ggggctggga aactcctgca aaactcgaga ccaggaagcc agcccgcacc
    ccaaccccca ccaaagccac ctactcttct tctgtgggag gccagtccac
    atccgctctc acccgagaga gatattcagc tggatccaaa gtgactgatg
    aagggaagga aatcatgtca agcgaagcct tgaaaaagct gccctgagac
    ggtgtcccgc cgaaagaatg ttggctcaat taagaaacat cagggagata
    aattcaaccc agtgtgtcta aaaatgacta caaaacgaag tttgtttgtg
    cggttggtac catgtcgctg tctacgaggg gaagaggaga ctgtcactac
    tcttgattat tctcattgca gcttagaaca agttccgaaa gagattttta
    cttttgaaaa aaccttggag gaactctatt tagatgctaa tcagattgaa
    gagcttccaa agcaactttt taactgtcag tctttacaca agctgagttt
    gccagacaat gatttaacaa cgttaccagc atccattgca aaccttatta
    atctcaggga actggatgtc agcaagaatg gaatacagga gtttccagaa
    aatataaaaa attgtaaagt tttgacaatt gtggaggcca gtgtaaaccc
    tatttccaag ctccctgatg gattttctca gctgttaaac ctaacccagt
    tgtatctgaa tgatgctttt cttgagttct tgccagcaaa ttttggcaga
    ttaactaaac tccaaatatt agagcttaga gaaaaccagt taaaaatgtt
    gcctaaaact atgaatagac tgacccagct ggaaagattg gatttgggaa
    gtaacgaatt cacggaagtg cctgaagtac ttgagcaact aagtggattg
    aaagagtttt ggatggatgc taatagactg acttttattc cagggtttat
    tggtagtttg aaacagctca catatttgga tgtttctaaa aataatattg
    aaatggttga agaaggaatt tcaacatgtg aaaaccttca agacctccta
    ttatcaagca attcacttca gcagcttcct gagactattg gttcgttgaa
    gaatataaca acgcttaaaa tagatgaaaa ccagttaatg tatctgccag
    actctatagg agggttaata tcagtagaag aactggattg tagtttcaat
    gaggttgaag ctttgccttc atctattggg cagcttacta acttaagaac
    ttttgctgct gatcataatt acttacagca gttgccccca gagattggaa
    gctggaaaaa tataactgtg ctgtttctcc attccaataa acttgagaca
    cttccagagg aaatgggtga tatgcaaaaa ttaaaagtca ttaatttaag
    tgataataga ttaaagaatt taccctttag ctttacaaag ctacagcaat
    tgacagctat gtggctctca gataatcagt ccaaacccct gatacctctt
    caaaaagaaa ctgattcaga gacccagaaa atggtgctta ccaactacat
    gttccctcaa cagccaagga ctgaggatgt tatgtttata tcagataatg
    aaagttttaa cccttcattg tgggaggaac agaggaaaca gcgggctcaa
    gttgcatttg aatgtgatga agacaaagat gaaagggagg cacctcccag
    ggagggaaat ttaaaaagat atccaacacc atacccagat gagcttaaga
    atatggtcaa aactgttcaa accattgtac atagattaaa agatgaagag
    accaatgaag actcaggaag agatttgaaa ccacatgaag atcaacaaga
    tataaataaa gatgtgggtg tgaagacctc agaaagtact actacagtaa
    aaagcaaagt tgatgaaaga gaaaaatata tgataggaaa ctctgtacag
    aagatcagtg aacctgaagc tgagattagt cctgggagtt taccagtgac
    tgcaaatatg aaagcctctg agaacttgaa gcatattgtt aaccatgatg
    atgtttttga ggaatctgaa gaactttctt ctgatgaaga gatgaaaatg
    gcggagatgc gaccaccatt aattgaaacc tctattaacc agccaaaagt
    cgtagcactt agtaataaca aaaaagatga tacaaaggaa acagattctt
    tatcagatga agttacacac aatagcaatc agaataacag caattgttct
    tctccatctc ggatgtctga ttcagtttct cttaatactg atagtagtca
    agacacctca ctctgctctc cagtgaaaca aactcatatt gatattaatt
    ccaaaatcag gcaagaagat gaaaatttta acagcctttt acaaaatgga
    gatattttaa acagttcaac agaggaaaag ttcaaagctc atgataaaaa
    agattttaac ttacctgaat atgatttgaa tgttgaagag cgattagttc
    taattgagaa aagtgttgac tcaacagcca cagctgatga cactcacaaa
    ttagatcata tcaatatgaa tcttaataaa cttataacta atgatacatt
    tcaaccagag atcatggaaa gatcaaaaac acaggatatt gtgcttggaa
    caagcttttt aagcattaat tctaaagagg aaactgagca cttggaaaat
    ggaaacaagt atcctaattt ggaatccgta aataaggtaa atggacattc
    tgaggaaact tcccagtctc ctaataggac tgaaccacat gacagtgatt
    gttctgttga cttaggtatt tccaaaagca ctgaagatct ctcccctcag
    aaaagtggtc cagttggatc tgttgtgaaa tctcatagca taactaatat
    ggagattgga gggctaaaaa tctatgatat tcttagtgat aatggacctc
    agcagccaag tacaaccgtt aaaatcacat ctgctgttga tggaaaaaat
    atagtcagga gcaagtctgc cacactgttg tatgatcaac cattgcaggt
    atttactggt tcttcctcat cttctgattt aatatcagga acaaaggcaa
    ttttcaagtt tgattcaaat cataatcccg aagagccaaa tataataaga
    ggccccacaa gtggcccaca atctgcacct caaatatatg gtcctccaca
    gtataatatc caatacagta gcagtgctgc agtcaaagac actttgtggc
    actccaaaca aaatccccaa atagaccatg ccagttttcc tcctcagctc
    cttcctagat cagagagcac agaaaatcaa agttatgcta aacattctgc
    caatatgaat ttctctaatc ataacaatgt tcgagctaat actgcatacc
    atttacatca gagacttggc ccagcaagac atggggaaat gtgggccatc
    tcaccaaacg accgacttat tcctgcagta actcgaagta caatccagcg
    acaaagtagt gtgtcctcca cagcctctgt aaatcttggt gatccaggct
    ctacaaggcg ggctcagatt cctgaaggag attatttatc atacagagag
    ttccactcag cgggaagaac tcctccaatg atgccaggat cacagagacc
    cctttctgca cgaacataca gcatagatgg tccaaatgca tcaagacctc
    agagtgctcg accctctatt aatgaaatac cagagagaac tatgtcagtt
    agtgatttca attattcacg gactagtcct tcaaaaagac caaatgcaag
    ggttggttct gagcattctt tattagatcc tccaggaaaa agtaaagttc
    ctcgtgactg gagagaacaa gtacttcgac atattgaagc caaaaagtta
    gaaaagatgc ctttgagtaa tggacagatg ggccagcctc tcaggcctca
    ggcaaattat agtcaaatac atcacccccc tcaggcatct gtggcaaggc
    atccctctag agaacaacta attgattact tgatgctgaa agtggcccac
    cagcctccat atacacagcc ccattgttct cctagacaag gccatgaact
    ggcaaaacaa gagattcgag tgagggttga aaaggatcca gaacttggat
    ttagcatatc aggtggtgtc gggggtagag gaaacccatt cagacctgat
    gatgatggta tatttgtaac aagggtacaa cctgaaggac cagcatcaaa
    attactgcag ccaggtgata aaattattca ggctaatggc tacagtttta
    taaatattga acatggacaa gcagtgtcct tgctaaaaac tttccagaat
    acagttgaac tcatcattgt acgagaagtt tcctcataag cactgtggac
    aaaaaaagcg gggaagacag caagatttat tggaagatac ttacagggga
    aattaatatt ttgactattt ttatatataa agaagaactc aaaaaattat
    gttcaaattt gtacattaat gaaataatgg ataaaggaga ctgttgaatt
    cataccatat aaaacttgtt aggtttttaa acatagcaat caaggctaca
    aaaacaaacc tgtgttgttt ttgtatagat tgtaggttta tttttggatt
    tcatatacat gactgaactg tgtgcaaggc aatagttagc cttgatttta
    gcccagagac agatggcaga gctatctctc tcatagcttt tatgccctta
    tttttattca actggtatta atgtttttct cctgaaacta ctttttttga
    tgtgggcaag agatttgaag tgttggcttt tgctatgtgc atattgaatt
    gaagagtgag taggtgaagg tggtgctggt gggttcactt tccaaggcca
    gactaaaaca gttattttct ataaaaatct ggaagcaaag aatggggatg
    gggagagcta cgtggtagta tgtttttatt aggagaataa tgcaataaaa
    tatgtaatgt cttttttata aagcaaaaaa gacaataatt gcatttatga
    gctcggcagg atctgttctt gtcatagcca ttgactatac atttgctact
    ggtgattcag tttttaattt tttagtcaca ggaaattttt aactctactg
    tagatgcatg tccatgcatt ttctgtgtta tggaaatcca ctgatttttt
    tttttttttc aaatggtggt acttgcaatc tgttttataa ttagtgctcc
    atttaaatct aatttataat ttttatttta agcagcaaat gaaacaaaaa
    tggccagttt taagattgtg ttgcctgtaa cacaaaatgt tacgaaggtt
    taggaaagcc tctttgattt ttgtttggcc ttgcattggc ccttggtaaa
    gtaaaaggaa acagtacact tggagctagg aaaccaaagc aagctttgtg
    aaactggcac agtgatagag aattgctgtg gagagttata gagcaaaggg
    atgggtcctt gaggcctgcc agtgtgtaaa ggtgttcaaa taaagggctg
    tttctacagg taacattaaa tgtgaactca acacttccag agtctttaaa
    gggtttctat gtgtatcagt gtaatagtgt tttaccacca actgcctttc
    tttgttccta gttactgtaa caaatatttg atgatagagg tttattaatt
    ttgtttatcc agaccattaa ttttatttgt ttttgtctat gtaatcaaat
    aaaatttgag taacatgtaa tggtaaggat taatgcatgg ttatttggac
    cagaaaaaag tgccatagaa gaccaataac tgtttagttg aggctagtct
    ggaacctttc attagagcaa tatttggtta ttgcacttca tttttattta
    ctaagaaatg caatttggga atttttaatc tgttatgctt tgtttatcaa
    ccttgatttt aattaagact tttataagac tagcttaaaa caccaaccaa
    cattattttt gcaaaagtga gttggactca ctttccattc ttgctagtca
    gagtaagtag gcagcacttt taaaaatatg tgaactcaaa tattgcactt
    ctttcaagat gttatcaatt ggttattgta ctgtatagtt ttaataattt
    tgattgaaac cctttaacaa ctctttgtaa attttaactc attttagttg
    attttcagta ctatttacat aggaattgat ttttatggat atagtagaag
    aaatgtgctg tattttgata aaattcactt attgtatgtg tgttgtaatc
    taaaaaaaaa aagaatgaca aacagcttct ttaagacaaa aaaaaaaaaa
    aaaaaaaaa
  • Erbin is a negative regulator of the Ras-Raf-Erk signaling pathway. Expression of Erbin decreases neuregulin-induced transcription of AChR ε-subunit gene, an event that requires Erk activation. Although it interacts with the ErbB2 C-terminus through the PDZ domain, Erbin has no effect on ErbB2 tyrosine phosphorylation and binding to adaptor proteins Shc or Grb2. In contrast, expression of Erbin greatly impairs Erk activation by ligands that activate receptor tyrosine kinases, without causing a significant change in AKT activity. It is now shown herein that Erbin diminishes the ability of Ras but not Raf-1 to activate Erk. Consistently, Erbin binds only to active Ras, as opposed to inactive Ras or Raf, resulting in inhibition of the interaction between Ras and Raf both in vivo and in vitro. As a suppressor of the Ras by disrupting Raf binding to active Ras, Erbin acts to suppress tumorigenesis of cancer cells, especially breast and prostate cancer cells. The control of tumorigenesis by increasing level of Erbin in malignant tissue by various means, especially through gene therapy, to obtain a blood or target tissue cell concentration of about 1 μM to 100 μM concentration would be appropriate for control of malignancies. [0010]
  • Materials and Methods: [0011]
  • Plasmid Construction—The human Erbin N-terminal domain (aa 1-391) consisting of 16 LRRs was generated by PCR amplification using sense primer containing BamHI and antisense primer containing XhoI. The resulting 1.2 kb-fragment was digested with BamHI and XhoI, and subcloned in the BamHI-SalI sites of yeast vector pGBT9 downstream of the Gal4 DNA binding domain (Clontech). Myc-Erbin LRR, Myc-ErbinD965 and Myc-DPDZ were generated by introducing a stop codon after the LRR domain following aa 965 or aa 1279 in pRK5-Myc-Erbin. The N-terminal deletion mutant (pRK5-Erbin965) was described previously (Huang, Y. Z., Wang, Q., Xiong, W. C., and Mei, L. (2001) J Biol Chem 276, 19318-19326); and Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adelaide, J., Margolis, B., and Birnbaum, D. (2000) Nat Cell Biol 2, 407-414). A fragment encoding the full-length Akt cDNA generated by PCR using sense primer containing EcoRI and antisense primer containing XhoI. The resulting 1.6 kb-fragment was digested with EcoRI and XhoI, and subcloned into EcoRI-XhoI sites of the mammalian expression vector pCS2+MT (for the Myc tag at the amino terminus). Wild type-ErbB2 and constitutive active form of ErbB2 (NeuT) (generously provided by Dr. M. C. Hung, University of Texas M. D. Anderson Cancer Center) were subcloned downstream of the Flag-tag and an artificial signal peptide in pCMV. pCMV-Flag-Erk1 was generously provided by Dr. Mike Weber (University of Virginia). Flag-Ras, Flag-RasV12, Flag-RasN17, GST-Raf-C4, and GST-Raf-BXB were described as previously (Zang, M., Hayne, C., and Luo, Z. (2002) J Biol Chem 277, 4395-4405). [0012]
  • Cell Culture and Transfection—HEK 293 cells and COS-7 cells were cultured as described previously (Huang, supra). The C2C2 cells were maintained as undifferentiated myoblasts in DMEM with high glucose supplemented with 20% fetal bovine serum, and 0.5% chicken embryo extract. Fusing of myoblasts into myotubes was induced by culturing myoblasts for 48 hours in differentiation medium DM (DMEM plus 4% horse serum). Mouse lung epithelial Mv1Lu cells were maintained in DMEM plus 10% fetal bovine serum (FBS). Rat pheochromocytoma-derived PC12 cells were grown in DMEM supplemented with 10% FBS and 5% horse serum. HEK 293, COS-1 and C2C12 cells were transfected with the standard calcium phosphate technique. PC12 cells and Mv1Lu cells were transfected with SuperFect regents (Qiagen). Two days after transfection, cells were washed with PBS and lysed in the modified RIPA buffer containing 20 mM sodium phosphate, pH 7.4, 50 mM sodium fluoride, 40 mM sodium pyrophosphate, 1% Triton X-100, 2 mM sodium vanadate, 10 mM p-nitrophenyl phosphate, and protease inhibitors. Lysed cells were incubated on ice for 20 min and centrifuged at 13,000×g for 10 min at 4 C. The clear supernatant was designated as cell lysates. [0013]
  • Immunoprecipitation and Immunoblottina—Cell lysates (˜400 μg of protein) were incubated without or with indicated antibodies one hour at 40° C. and subsequently with protein A- or protein G-agarose beads overnight at 4° C. on a rotating platform. After centrifugation, beads were washed five times with the modified RIPA buffer. Bound proteins were eluted with the SDS sample buffer, resolved by SDS-PAGE and transferred onto nitrocellulose membranes (Schleicher and Schuell). Nitrocellulose membranes were incubated at room temperature for one hour in the blocking buffer containing Tris-buffered saline with 0.1% Tween (TBS-T) containing 5% milk or 5% BSA followed by an incubation with indicated antibodies in the blocking buffer. After washing 3 times for 5 min each with TBS-T, the membrane was incubated with horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit IgG (Amersham Pharmacia Biotech) followed by washing. Immunoreactive bands were visualized with enhanced chemiluminescence substrate (Pierce). In some experiments, the nitrocellulose filter was incubated in a buffer containing 62.5 mM Tris/HCl, pH 6.7, 100 mM β-mer-captoenthanol, and 2% SDS at 50° C. for 30 min, and washed with 0.1% Tween 20 in 50 mM TBS at room temperature for 1 hr, and reblotted with different antibodies. The following antibodies were used: Flag (M2, Sigma), Myc (9E10, Santa Cruz), phospho-MAPK (Promega), phospho-Akt (Ser473, New England Biolab) and Erbin. [0014]
  • Luciferase Assay—Myoblasts were co-transfected with or without Myc-Erbin, plus the ε-subunit promoter-luciferase transgene that contains 416 nucleotides of the 5′UTR of the ε-subunit gene (25) and a control plasmid pRL-SV40 (Promega). Twenty four hours after transfection, the myoblasts were incubated in DM to induce myotube formation. Myotube formation was complete 48 hours after switch to DM. The C2C12 myotubes were stimulated with neuregulin at a final concentration of 10 Nm at 37° C. for 24 hours. Mv1Lu cells were transiently transfected with the promoter reporter construct p3TP-Lux, which promoter contains three AP-1 sites and the plasminogen activator inhibitor-1 (PAI-1) promoter and firefly luciferase. pRL-SV40 that express Renilla luciferase under the control of SV40 promoter was cotransfected as a control to monitor the transfection efficiency. Fourty eight hours after transfection, cells were lysed and activities of the two different luciferases were assayed with respective substrates with a dual luciferase assay kit (Promega). [0015]
  • Differentiation of PC12 cells—PC12 cells were cotransfected pEGFP with empty vector pRK5-Myc, Myc-Erbin or its mutants, or Erbin RNAi duplex. Forty eight hours after transfection, PC12 cells were stimulated by 100 ng/ml or 20 ηg/ml NGF for 2 days. Cells were examined by fluorescence microscopy. Cells with processes 1.5 times longer than the diameter of the cell body were considered to be differentiated. [0016]
  • Inhibition of Erbin expression by RNAi—The target region of siRNA was 100 nt downstream of the start codon, which contained approximately 50% G/C content. The nucleotide sequence was 5′ UAG ACU GAC CCA GCU GGA A dTdT 3′ (nt 866-884) (Borg, J. P., Marchetto, S., Le Bivic, A., Ollendorff, V., Jaulin-Bastard, F., Saito, H., Fournier, E., Adelaide, J., Margolis, B., and Birnbaum, D. (2000) Nat Cell Biol 2, 407-414). The NCBI sequence bank was searched against this segment Cof DNA using the blast program, which revealed no match, suggesting of the specificity of target recognition by siRNA. The 21-nucleotide RNAs were chemically synthesized by Dharmacon Research Inc. Synthetic oligonucleotides were deprotected and gel-purified. To demonstrate the silencing effect of endogenous Erbin expression by siRNA, cells in 60 mm-culture dish were co-transfected with empty vector pEGFP and with siRNA duplex using the SuperFect kit (Qiagen). Briefly, 2 mg of pEGFP and 30 ml of 20 mM RNAi duplex were mixed with 300 ml of Opti-MEM (GIBCO-BRL). After incubating 10 min at room temperature, Opti-MEM was added to obtain a final volume of 1 ml. Cells were incubated with the mixture for 2-3 hours at 37° C. and 5% CO before the addition of 5 ml of growth medium. Seventy two hours after transfection, cells were resuspended in PBS buffer. GFP-positive cells were collected by fluorescence-activated cell sorting (FACS) analysis. Cells were lysed in modified RIPA buffer and lysates were subjected to immunoblotting for expression of Erbin. In parallel experiments, GFP-positive PC12 cells were scored for differentiation. [0017]
  • Protein Assay—Protein was assayed with Coomassie Protein Assay Regent (Pierce) using bovine serum albumin as a standard. [0018]
  • Erbin inhibits neuregulin-induced transcription of the AChR ε-subunit gene and Erk activation—It was found that transcription of AChR subunit genes is increased by neuregulin, a ligand that activates the ErbB2 receptor tyrosine kinase. Previous studies in this laboratory and by others have demonstrated that neuregulin-induced AChR expression requires ErbB2 tyrosine phosphorylation and activation of the Ras-Raf-Erk signaling pathway. It now is seen that Erbin, interacting with ErbB2, plays a role in regulating neuregulin signaling. To test this hypothesis, it was useful to examine the effect of Erbin on the promoter activity of ε416-Luc, a transgene reporter that contains 416 nucleotides of the 5′UTR of the -subunit gene. Expression of this transgene is up-regulated by neuregulin or Ras- or Raf-activation and requires Erk activation. Unexpectedly, it was found that co-expression of Erbin inhibited neuregulin-activated expression of the ε416-Luc transgene, suggesting that Erbin may regulate the Erk activation. [0019]
  • To test this hypothesis, it was useful to characterize effects of Erbin on Erk1 activation in COS-7 cells. Flag-Erk1 was activated in response to the growth factor NRG in cells cotransfected with ErbB4. Coexpression of Erbin caused a significant decrease in the level of phopho-Erk, indicating that Erbin negatively regulate the Ras-Raf-MEKErk pathway. The inhibitory effect of Erbin featured the following: (1) it was dose-dependent; (2) Erbin did not seem to delay the peak Erk activation that usually occurred within 5 min of stimulation; (3) the inhibition was not growth factor-specific. In addition, expression of Erbin inhibited EGF- and NGF-induced Erk activation and (4) it was Erk activation-specific, since expression of Erbin had no apparent effect on NRG activation of Akt. Thus, the results demonstrate that Erbin specifically inhibits Erk activation with little effect on the PI3 kinase pathway. [0020]
  • To identify the domain that inhibits the Erk activation, we examined the effect of a series of Erbin mutations. The results revealed that the inhibition of Erk did not require PDZ domain, which interacts with ErbB2 or the region between the LRR domain and the PDZ domain. In contrast, deletion of the LRR domain disabled Erbin to inhibit Erk activation. Furthermore, it was demonstrated that the LRR domain was sufficient to mediate the inhibitory effect. These results are in agreement with the differentiation assay and thus indicates that Erbin plays an important role in regulating the Ras-Raf-MEK-Erk pathway. [0021]
  • Erbin inhibits Erk activation by Ras—An attempt was made to dissect the position for Erbin action by walking upstream of Erk. Since ErbB2 directly interacts with the cytoplasmic domain of tyrosine kinase receptors, it is possible that Erbin interferes with the tyrosine kinase activation and/or subsequent binding to adaptor proteins. To test these hypotheses, it was decided to take the advantage of NeuT, an active form of ErbB2 (Bargmann, C. I., Hung, M. C., and Weinberg, R. A. (1986) Cell 45, 649-657). When expressed in COS1 cells, NeuT was tyrosine-phosphorylated, resulting in an increase in the promoter activity of p3TP-Lux. When NeuT was immunoprecipitated, association of Shc and Grb2 could be easily detected. Coexpression of Erbin had no effect on either tyrosine phosphorylation of NeuT or its association with Shc and Grb2. However, the NeuT-induced promoter activity of 3TP was greatly inhibited by Erbin, indicating that the site of Erbin action is downstream of the adapter proteins. Further examination was conducted to determine whether Erbin inhibits Erk activation by Raf or Ras. Since expression of the active mutant of Raf bypasses the requirement of upstream components for the MEK/Erk activation, Erbin would attenuate the Erk activation by active Raf, if it acted downstream of Raf. The results showed that coexpression of Erbin with active Raf was essentially without an effect on the Erk activation. Conversely, inhibition of Erk activation by active Ras was evidently observed. These results indicate that Erbin acts above Raf, likely at the level of Ras. [0022]
  • Erbin disrupts the Ras-Raf interaction—In considering the mechanism of the Erbin-induced inhibition of the Erk pathway, it was postulated that Erbin inhibits the interaction between active Ras and Raf by competitive binding to either of them, or diminishing the GTP-bound form of Ras. To test this, an active mutant of Ras (Flag-RasV12) was coexpressed with GST-Raf1 into HEK293 cell. Flag-RasV12 was found to copurify with GST-Raf1. In a reciprocal study, Raf1 was detected in the immunoprecipitates of active Ras. Remarkably, coexpression of Erbin decreased the interaction between active Ras and Raf. In an alternative study, the Ras pull-down assay developed by Rooij and Bos in which they exploited the nature of high affinity of GTP-Ras for the Ras-binding domain (RBD) of Raf-1, as compared with GDP-Ras was employed. The RBD (aa 50-150) was expressed as a GST-fusion protein and used to pull down GTP-Ras that had been activated inside cells cotransfected with or without Erbin. In cells transfected with Flag-Ras, GTP-Ras was recovered by the GST-Raf-RBD beads. Expression of Erbin inhibited the interaction of Raf with growth factor-activated Ras, accompanied by a decrease in phospho-Erk1. These results indicate that Erbin inhibits the Erk pathway by disrupting the interaction between active Ras and Raf. [0023]
  • Studies were conducted to determine whether Erbin directly bound to active Ras or Raf in a manner to prevent them from forming a complex. When recombinant Erbin was isolated from HEK293 cells contransfected with Raf-1, no association was found between these two proteins. A parallel experiment was performed with Erbin and Ras. Only the active RasV12 was co-immunoprecipitated with Erbin, as opposed to the dominant negative mutant Ras. These clearly indicate that Erbin competes with Raf1 by binding to active Ras. [0024]
  • Inhibition of NGF-induced PC12 cell differentiation by Erbin—To further study the physiological importance of the Ras inhibition by Erbin, the effect of its overexpression on neuronal differentiation of rat pheochromocytoma (PC12) cells was examined. By chronic incubation with NGF, these cells differentiated developed sympathetic neuron-like phenotypes. The NGF-treated cells stopped to divide and in turns developed long, sometimes branched processes. The signaling events have been well characterized during NRG-induced differentiation of PC12 cells in which the Ras-Raf-Erk pathway plays an essential role. The inhibition of Erk activation by Erbin prompted an extended study to more broadly examine its effect on NRG-induced differentiation of PC12 cells. Expression of enhanced green fluorescent protein (EGFP) and the pRK5-Myc empty vector (control) had no apparent effect on the differentiation, whereas Erbin-transfected PC12 cells exhibited altered morphology. The neurites became shorter and were less branched. Under the control condition, cells bearing neurites 1.5 times longer than the cell body accounted for 60±5% of the total cell population, whereas the number of differentiated cells are significantly reduced after Erbin transfection. Ectopic expression of the LRR domain showed similar effect on differentiation, suggesting the inhibitory activity was contained in this domain. In contrast, cells transfected with Δ965 encoding C-terminal domain of Erbin appeared to have normal differentiation. [0025]
  • To verify the inhibitory effect of Erbin on PC12 cell differentiation, the effect of suppressed Erbin expression in PC12 cells was examined. RNA interference (RNAi) techniques were used for this purpose. As an emerging new technique to diminish expression of specific genes at a cellular level, sequence-specific double-stranded RNA are first employed in evolutionarily diverse organisms including plants, fungi, and metazoans (Hammond, S. M., Caudy, A. A., and Hannon, G. J. (2001) Nat Rev Genet 2, 110-119). Recently, RNAi has been shown to specifically suppress the expression of endogenous and heterologous genes in mammalian cell lines. Thus, 21 nucleotide RNAi duplexes directed against Erbin (nucleotides 866-884) were synthesized and transfected in PC12 cells to suppress the expression of endogenous Erbin. Two days after transfection, cells expressing co-transfected EGFP were sorted out and analyzed for Erbin expression by Western blot. Expression of Erbin in RNAi-transfected cells was significantly decreased in comparison with missense RNAi-transfected cells (control). The suppressing effect by Erbin RNAi appeared to be specific since it had no effect on expression of endogenous Erk1. Moreover, expression of cotransfected EGFP was unaffected. Having demonstrated that sense RNAi inhibits expression of endogenous Erbin, RNAi-transfected PC12 cells were challenged with 20 ng/ml NGF to induce differentiation. To capture the maximal effect of Erbin RNAi, a sub-maximal effective concentration of NGF was used, as at this concentration, NGF caused differentiation of only 25±2% PC12 cells. Remarkably, suppressing Erbin expression by sense RNAi enhanced NGF-mediated cell differentiation (52±2%), while missense RNAi had no significant effect (18±2%). These data reinforce the conclusion that Erbin inhibits NGF-induced differentiation of PC12 cells. [0026]
  • Preparation and administration of viral vectors. The costruction of adenovirus is carried out according to established protocols (Proc. Natl. Acad. Sci. USA (1998) 95: 2509-2514) using a set of commercially available plasmids. Briefly, DNA encolding the full length of Erbin or the LRR domain (Erbin-LRR) is coded into pAdTrack-CMV. Ad-Erbin or Erbin-LRR and control AdGFP adenoviruses are generated in BJ5183 (available from American Type Culture Collection (ATCC) as deposit JHU-18) bacterial cells by homologous recimbination of the viral pAdEasy-1 and pAdTrack CMV-Erbin or Erbin-LRR and pAdTrack-CMV, respectively. Cells available from ATCC under deposit number CRL-1573 known as 293 cells are used as hosts for viral productions by known methods. (See Neuron. (2002), 35:489-505) [0027]
  • The adenoviruses expressing Erbin or Erbin-LRR are injected into the tumor tissue to infect cancer cells, particularly breast or prostate cancer cells. [0028]
  • Administration of Erbin DNA into tumors. Mice are anesthetized with phenobarbital sodium. Tumor tissues are injected with 100 μg of closed circular DNA (pcDNA3-Erbin or Erbin-LRR) at concentration of 1.0 μg/μl in saline using a syringe with a 27-gauge needle. To enhance the transfection efficiency, injected tumor tissues are subjected to electroporation with a pair of tungsten needles inserted into the tumor encompassing DNA injection sites. Electric pulses are delivered using an electric pulse generator. [0029]
  • Monitoring Erbin expression. Erbin expression in tumor tissues and cells may be monitored by two methods: Western blot and immunohitochemical analysis, both using anti-Erbin antibody. [0030]
  • Western blot: Tumor tissue or cell lysates (about 400 μg of protein) from the suspect tissue and from control, normal tissue are resolved by SDS-PAGE, and transferred into nitrocellulose membranes. Nitrocellulose membranes are incubated at room temperature for one hour in the blocking buffer containing Tris-buffered saline with 0.1% Tween (TBS-T) containing 5% milk followed by incubation with anti-Erbin antibody in the blocking buffer. After washing three times for 5 minutes each with TBS-T, the membrane is incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham Biosciences) followed by washing. Immunoreactive bands are visualized with enhanced chemiluminescence substrate (Pierce). [0031]
  • Immunohistochemical analysis. Tumor tissues are rapidly dissected and frozen in isopentane cooled with dry ice. Ten μM sections are prepared using a cryostat, thaw mounted on gelatin-coated slides and stored at −80°C. Sections of tumor tissue sections are incubated with 2% normal goat serum (Vector Laboratories, Burlingame, Calif.) in PBS for 1 hour at room temperature to reduce background staining and then incubated with the affinity-purified and anti-Erbin antibody in 2% normal goat serum in PBS overnight at 4° C. After wiashing the sections five times with PBS, each for 30 minutes, the sections are incubated with a flourescein istothiocyanate-conjugated anti-rabbit antibody (Zymed Laboratories Inc., San Francisco, Calif.) or visualized by the established DAB method. Fluorescent images are captured on Sony CCD camera mounted on a Nikon E600 microsope using Photoshop imaging software. The amount of Erbin is then determined. [0032]
  • In each instance, the amount of Erbin as measured is measured against standards and against the amount of Erbin in normal tissues. It is also possible to evaluate progression of disease by measuring the amount of Erbin in samples from target tissue repeatedly. [0033]
  • Identification of Erbin mutants. Tumor tissue samples are collected from patients with breast or prostate cancer and from health controls, matched for geographical origin. DNA is isolated and collected in tripotassium EDTA strile tubes and immediately stored at −70° C. Genomic DNA extraction is performed on the tissue. The DNA sequence encoding the LRR domain is subjected to analysis of the Erbin gene. The polymorphism is identified using ARMS-PCR as previously described (Genes Immunity (2002) 3:30-33). [0034]
  • It appears that following Raf activation, Erbin functions to kick Raf off the plasma membrane by competing with Raf in binding to active Ras. Thus, overexpression of Erbin diminishes the accessibility of Ras-GTP to Raf-1. Alternatively, Erbin may compete with Sur-8 for binding to Ras and then dissociate the Sur 8/Ras/Raf ternary complex, resulting in down-regulation of the Erk pathway. It is conceivable that Erbin may act more quickly and efficiently than Sur 8, as it is enriched at the plasma membrane. Active mutations of the Ras gene renders it the most frequent oncogene found in human cancers and even more, many other oncogenes exploit Ras and its downstream cohorts to execute their functions. Thus, the use of Erbin for inhibitory mechanisms and blockers for this pathway is indicted as a means of inhibiting growth of malignant cells. The method involved administration of a proliferation inhibiting effective amount of Erbin or the administration of a vector which gives rise to production of a proliferation inhibiting effective amount of Erbin. [0035]
  • 1 1 6409 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 1 AAAGATCTTT TTTTTTTTTT TTTCTTTTTT TTTCGGCGGA GATCCTCGTT GGGGCTGGGA 60 AACTCCTGCA AAACTCGAGA CCAGGAAGCC AGCCCGCACC CCAACCCCCA CCAAAGCCAC 120 CTACTCTTCT TCTGTGGGAG GCCAGTCCAC ATCCGCTCTC ACCCGAGAGA GATATTCAGC 180 TGGATCCAAA GTGACTGATG AAGGGAAGGA AATCATGTCA AGCGAAGCCT TGAAAAAGCT 240 GCCCTGAGAC GGTGTCCCGC CGAAAGAATG TTGGCTCAAT TAAGAAACAT CAGGGAGATA 300 AATTCAACCC AGTGTGTCTA AAAATGACTA CAAAACGAAG TTTGTTTGTG CGGTTGGTAC 360 CATGTCGCTG TCTACGAGGG GAAGAGGAGA CTGTCACTAC TCTTGATTAT TCTCATTGCA 420 GCTTAGAACA AGTTCCGAAA GAGATTTTTA CTTTTGAAAA AACCTTGGAG GAACTCTATT 480 TAGATGCTAA TCAGATTGAA GAGCTTCCAA AGCAACTTTT TAACTGTCAG TCTTTACACA 540 AGCTGAGTTT GCCAGACAAT GATTTAACAA CGTTACCAGC ATCCATTGCA AACCTTATTA 600 ATCTCAGGGA ACTGGATGTC AGCAAGAATG GAATACAGGA GTTTCCAGAA AATATAAAAA 660 ATTGTAAAGT TTTGACAATT GTGGAGGCCA GTGTAAACCC TATTTCCAAG CTCCCTGATG 720 GATTTTCTCA GCTGTTAAAC CTAACCCAGT TGTATCTGAA TGATGCTTTT CTTGAGTTCT 780 TGCCAGCAAA TTTTGGCAGA TTAACTAAAC TCCAAATATT AGAGCTTAGA GAAAACCAGT 840 TAAAAATGTT GCCTAAAACT ATGAATAGAC TGACCCAGCT GGAAAGATTG GATTTGGGAA 900 GTAACGAATT CACGGAAGTG CCTGAAGTAC TTGAGCAACT AAGTGGATTG AAAGAGTTTT 960 GGATGGATGC TAATAGACTG ACTTTTATTC CAGGGTTTAT TGGTAGTTTG AAACAGCTCA 1020 CATATTTGGA TGTTTCTAAA AATAATATTG AAATGGTTGA AGAAGGAATT TCAACATGTG 1080 AAAACCTTCA AGACCTCCTA TTATCAAGCA ATTCACTTCA GCAGCTTCCT GAGACTATTG 1140 GTTCGTTGAA GAATATAACA ACGCTTAAAA TAGATGAAAA CCAGTTAATG TATCTGCCAG 1200 ACTCTATAGG AGGGTTAATA TCAGTAGAAG AACTGGATTG TAGTTTCAAT GAGGTTGAAG 1260 CTTTGCCTTC ATCTATTGGG CAGCTTACTA ACTTAAGAAC TTTTGCTGCT GATCATAATT 1320 ACTTACAGCA GTTGCCCCCA GAGATTGGAA GCTGGAAAAA TATAACTGTG CTGTTTCTCC 1380 ATTCCAATAA ACTTGAGACA CTTCCAGAGG AAATGGGTGA TATGCAAAAA TTAAAAGTCA 1440 TTAATTTAAG TGATAATAGA TTAAAGAATT TACCCTTTAG CTTTACAAAG CTACAGCAAT 1500 TGACAGCTAT GTGGCTCTCA GATAATCAGT CCAAACCCCT GATACCTCTT CAAAAAGAAA 1560 CTGATTCAGA GACCCAGAAA ATGGTGCTTA CCAACTACAT GTTCCCTCAA CAGCCAAGGA 1620 CTGAGGATGT TATGTTTATA TCAGATAATG AAAGTTTTAA CCCTTCATTG TGGGAGGAAC 1680 AGAGGAAACA GCGGGCTCAA GTTGCATTTG AATGTGATGA AGACAAAGAT GAAAGGGAGG 1740 CACCTCCCAG GGAGGGAAAT TTAAAAAGAT ATCCAACACC ATACCCAGAT GAGCTTAAGA 1800 ATATGGTCAA AACTGTTCAA ACCATTGTAC ATAGATTAAA AGATGAAGAG ACCAATGAAG 1860 ACTCAGGAAG AGATTTGAAA CCACATGAAG ATCAACAAGA TATAAATAAA GATGTGGGTG 1920 TGAAGACCTC AGAAAGTACT ACTACAGTAA AAAGCAAAGT TGATGAAAGA GAAAAATATA 1980 TGATAGGAAA CTCTGTACAG AAGATCAGTG AACCTGAAGC TGAGATTAGT CCTGGGAGTT 2040 TACCAGTGAC TGCAAATATG AAAGCCTCTG AGAACTTGAA GCATATTGTT AACCATGATG 2100 ATGTTTTTGA GGAATCTGAA GAACTTTCTT CTGATGAAGA GATGAAAATG GCGGAGATGC 2160 GACCACCATT AATTGAAACC TCTATTAACC AGCCAAAAGT CGTAGCACTT AGTAATAACA 2220 AAAAAGATGA TACAAAGGAA ACAGATTCTT TATCAGATGA AGTTACACAC AATAGCAATC 2280 AGAATAACAG CAATTGTTCT TCTCCATCTC GGATGTCTGA TTCAGTTTCT CTTAATACTG 2340 ATAGTAGTCA AGACACCTCA CTCTGCTCTC CAGTGAAACA AACTCATATT GATATTAATT 2400 CCAAAATCAG GCAAGAAGAT GAAAATTTTA ACAGCCTTTT ACAAAATGGA GATATTTTAA 2460 ACAGTTCAAC AGAGGAAAAG TTCAAAGCTC ATGATAAAAA AGATTTTAAC TTACCTGAAT 2520 ATGATTTGAA TGTTGAAGAG CGATTAGTTC TAATTGAGAA AAGTGTTGAC TCAACAGCCA 2580 CAGCTGATGA CACTCACAAA TTAGATCATA TCAATATGAA TCTTAATAAA CTTATAACTA 2640 ATGATACATT TCAACCAGAG ATCATGGAAA GATCAAAAAC ACAGGATATT GTGCTTGGAA 2700 CAAGCTTTTT AAGCATTAAT TCTAAAGAGG AAACTGAGCA CTTGGAAAAT GGAAACAAGT 2760 ATCCTAATTT GGAATCCGTA AATAAGGTAA ATGGACATTC TGAGGAAACT TCCCAGTCTC 2820 CTAATAGGAC TGAACCACAT GACAGTGATT GTTCTGTTGA CTTAGGTATT TCCAAAAGCA 2880 CTGAAGATCT CTCCCCTCAG AAAAGTGGTC CAGTTGGATC TGTTGTGAAA TCTCATAGCA 2940 TAACTAATAT GGAGATTGGA GGGCTAAAAA TCTATGATAT TCTTAGTGAT AATGGACCTC 3000 AGCAGCCAAG TACAACCGTT AAAATCACAT CTGCTGTTGA TGGAAAAAAT ATAGTCAGGA 3060 GCAAGTCTGC CACACTGTTG TATGATCAAC CATTGCAGGT ATTTACTGGT TCTTCCTCAT 3120 CTTCTGATTT AATATCAGGA ACAAAGGCAA TTTTCAAGTT TGATTCAAAT CATAATCCCG 3180 AAGAGCCAAA TATAATAAGA GGCCCCACAA GTGGCCCACA ATCTGCACCT CAAATATATG 3240 GTCCTCCACA GTATAATATC CAATACAGTA GCAGTGCTGC AGTCAAAGAC ACTTTGTGGC 3300 ACTCCAAACA AAATCCCCAA ATAGACCATG CCAGTTTTCC TCCTCAGCTC CTTCCTAGAT 3360 CAGAGAGCAC AGAAAATCAA AGTTATGCTA AACATTCTGC CAATATGAAT TTCTCTAATC 3420 ATAACAATGT TCGAGCTAAT ACTGCATACC ATTTACATCA GAGACTTGGC CCAGCAAGAC 3480 ATGGGGAAAT GTGGGCCATC TCACCAAACG ACCGACTTAT TCCTGCAGTA ACTCGAAGTA 3540 CAATCCAGCG ACAAAGTAGT GTGTCCTCCA CAGCCTCTGT AAATCTTGGT GATCCAGGCT 3600 CTACAAGGCG GGCTCAGATT CCTGAAGGAG ATTATTTATC ATACAGAGAG TTCCACTCAG 3660 CGGGAAGAAC TCCTCCAATG ATGCCAGGAT CACAGAGACC CCTTTCTGCA CGAACATACA 3720 GCATAGATGG TCCAAATGCA TCAAGACCTC AGAGTGCTCG ACCCTCTATT AATGAAATAC 3780 CAGAGAGAAC TATGTCAGTT AGTGATTTCA ATTATTCACG GACTAGTCCT TCAAAAAGAC 3840 CAAATGCAAG GGTTGGTTCT GAGCATTCTT TATTAGATCC TCCAGGAAAA AGTAAAGTTC 3900 CTCGTGACTG GAGAGAACAA GTACTTCGAC ATATTGAAGC CAAAAAGTTA GAAAAGATGC 3960 CTTTGAGTAA TGGACAGATG GGCCAGCCTC TCAGGCCTCA GGCAAATTAT AGTCAAATAC 4020 ATCACCCCCC TCAGGCATCT GTGGCAAGGC ATCCCTCTAG AGAACAACTA ATTGATTACT 4080 TGATGCTGAA AGTGGCCCAC CAGCCTCCAT ATACACAGCC CCATTGTTCT CCTAGACAAG 4140 GCCATGAACT GGCAAAACAA GAGATTCGAG TGAGGGTTGA AAAGGATCCA GAACTTGGAT 4200 TTAGCATATC AGGTGGTGTC GGGGGTAGAG GAAACCCATT CAGACCTGAT GATGATGGTA 4260 TATTTGTAAC AAGGGTACAA CCTGAAGGAC CAGCATCAAA ATTACTGCAG CCAGGTGATA 4320 AAATTATTCA GGCTAATGGC TACAGTTTTA TAAATATTGA ACATGGACAA GCAGTGTCCT 4380 TGCTAAAAAC TTTCCAGAAT ACAGTTGAAC TCATCATTGT ACGAGAAGTT TCCTCATAAG 4440 CACTGTGGAC AAAAAAAGCG GGGAAGACAG CAAGATTTAT TGGAAGATAC TTACAGGGGA 4500 AATTAATATT TTGACTATTT TTATATATAA AGAAGAACTC AAAAAATTAT GTTCAAATTT 4560 GTACATTAAT GAAATAATGG ATAAAGGAGA CTGTTGAATT CATACCATAT AAAACTTGTT 4620 AGGTTTTTAA ACATAGCAAT CAAGGCTACA AAAACAAACC TGTGTTGTTT TTGTATAGAT 4680 TGTAGGTTTA TTTTTGGATT TCATATACAT GACTGAACTG TGTGCAAGGC AATAGTTAGC 4740 CTTGATTTTA GCCCAGAGAC AGATGGCAGA GCTATCTCTC TCATAGCTTT TATGCCCTTA 4800 TTTTTATTCA ACTGGTATTA ATGTTTTTCT CCTGAAACTA CTTTTTTTGA TGTGGGCAAG 4860 AGATTTGAAG TGTTGGCTTT TGCTATGTGC ATATTGAATT GAAGAGTGAG TAGGTGAAGG 4920 TGGTGCTGGT GGGTTCACTT TCCAAGGCCA GACTAAAACA GTTATTTTCT ATAAAAATCT 4980 GGAAGCAAAG AATGGGGATG GGGAGAGCTA CGTGGTAGTA TGTTTTTATT AGGAGAATAA 5040 TGCAATAAAA TATGTAATGT CTTTTTTATA AAGCAAAAAA GACAATAATT GCATTTATGA 5100 GCTCGGCAGG ATCTGTTCTT GTCATAGCCA TTGACTATAC ATTTGCTACT GGTGATTCAG 5160 TTTTTAATTT TTTAGTCACA GGAAATTTTT AACTCTACTG TAGATGCATG TCCATGCATT 5220 TTCTGTGTTA TGGAAATCCA CTGATTTTTT TTTTTTTTTC AAATGGTGGT ACTTGCAATC 5280 TGTTTTATAA TTAGTGCTCC ATTTAAATCT AATTTATAAT TTTTATTTTA AGCAGCAAAT 5340 GAAACAAAAA TGGCCAGTTT TAAGATTGTG TTGCCTGTAA CACAAAATGT TACGAAGGTT 5400 TAGGAAAGCC TCTTTGATTT TTGTTTGGCC TTGCATTGGC CCTTGGTAAA GTAAAAGGAA 5460 ACAGTACACT TGGAGCTAGG AAACCAAAGC AAGCTTTGTG AAACTGGCAC AGTGATAGAG 5520 AATTGCTGTG GAGAGTTATA GAGCAAAGGG ATGGGTCCTT GAGGCCTGCC AGTGTGTAAA 5580 GGTGTTCAAA TAAAGGGCTG TTTCTACAGG TAACATTAAA TGTGAACTCA ACACTTCCAG 5640 AGTCTTTAAA GGGTTTCTAT GTGTATCAGT GTAATAGTGT TTTACCACCA ACTGCCTTTC 5700 TTTGTTCCTA GTTACTGTAA CAAATATTTG ATGATAGAGG TTTATTAATT TTGTTTATCC 5760 AGACCATTAA TTTTATTTGT TTTTGTCTAT GTAATCAAAT AAAATTTGAG TAACATGTAA 5820 TGGTAAGGAT TAATGCATGG TTATTTGGAC CAGAAAAAAG TGCCATAGAA GACCAATAAC 5880 TGTTTAGTTG AGGCTAGTCT GGAACCTTTC ATTAGAGCAA TATTTGGTTA TTGCACTTCA 5940 TTTTTATTTA CTAAGAAATG CAATTTGGGA ATTTTTAATC TGTTATGCTT TGTTTATCAA 6000 CCTTGATTTT AATTAAGACT TTTATAAGAC TAGCTTAAAA CACCAACCAA CATTATTTTT 6060 GCAAAAGTGA GTTGGACTCA CTTTCCATTC TTGCTAGTCA GAGTAAGTAG GCAGCACTTT 6120 TAAAAATATG TGAACTCAAA TATTGCACTT CTTTCAAGAT GTTATCAATT GGTTATTGTA 6180 CTGTATAGTT TTAATAATTT TGATTGAAAC CCTTTAACAA CTCTTTGTAA ATTTTAACTC 6240 ATTTTAGTTG ATTTTCAGTA CTATTTACAT AGGAATTGAT TTTTATGGAT ATAGTAGAAG 6300 AAATGTGCTG TATTTTGATA AAATTCACTT ATTGTATGTG TGTTGTAATC TAAAAAAAAA 6360 AAGAATGACA AACAGCTTCT TTAAGACAAA AAAAAAAAAA AAAAAAAAA 6409

Claims (6)

What we claim is:
1. A method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.
2. The method of claim 1 wherein the amount of Erbin administered is sufficient to provide an intracellular concentration of 1 μM to 100 μM of DNA which encodes Erbin into the cells.
3. The method of claim 1 wherein the DNA encoding Erbin is administered via viral vectors.
4. A method of evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue comprising:
1) obtaining tumor tissue or cell lysates and
2) measuring the amount of Erbin in the sample obtained in step 1.
5. The method of claim 4 wherein the amount of Erbin is evaluated by Western blot.
6. The method of claim 4 wherein the amount of Erbin is evaluated by immunohistochemical analysis.
US10/446,640 2002-05-29 2003-05-28 Erbin as a negative regulator of Ras-Raf-Erk signaling Abandoned US20040058359A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/446,640 US20040058359A1 (en) 2002-05-29 2003-05-28 Erbin as a negative regulator of Ras-Raf-Erk signaling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38360302P 2002-05-29 2002-05-29
US10/446,640 US20040058359A1 (en) 2002-05-29 2003-05-28 Erbin as a negative regulator of Ras-Raf-Erk signaling

Publications (1)

Publication Number Publication Date
US20040058359A1 true US20040058359A1 (en) 2004-03-25

Family

ID=29711929

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/446,640 Abandoned US20040058359A1 (en) 2002-05-29 2003-05-28 Erbin as a negative regulator of Ras-Raf-Erk signaling
US10/446,939 Expired - Lifetime US6825920B2 (en) 2002-05-29 2003-05-29 Method and system of determining chamber seasoning condition by optical emission

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/446,939 Expired - Lifetime US6825920B2 (en) 2002-05-29 2003-05-29 Method and system of determining chamber seasoning condition by optical emission

Country Status (5)

Country Link
US (2) US20040058359A1 (en)
JP (1) JP2005527984A (en)
AU (1) AU2003241474A1 (en)
TW (1) TWI280617B (en)
WO (1) WO2003103017A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10436717B2 (en) 2016-11-18 2019-10-08 Tokyo Electron Limited Compositional optical emission spectroscopy for detection of particle induced arcs in a fabrication process
US10446453B2 (en) 2017-03-17 2019-10-15 Tokyo Electron Limited Surface modification control for etch metric enhancement
US10692705B2 (en) 2015-11-16 2020-06-23 Tokyo Electron Limited Advanced optical sensor and method for detecting an optical event in a light emission signal in a plasma chamber
US10773282B2 (en) 2016-03-31 2020-09-15 Tokyo Electron Limited Controlling dry etch process characteristics using waferless dry clean optical emission spectroscopy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4411215B2 (en) 2002-11-11 2010-02-10 株式会社日立国際電気 Substrate processing apparatus and semiconductor device manufacturing method
US7147747B2 (en) * 2003-03-04 2006-12-12 Hitachi High-Technologies Corporation Plasma processing apparatus and plasma processing method
KR100557673B1 (en) * 2003-12-22 2006-03-06 어댑티브프라즈마테크놀로지 주식회사 Method for seasoning plasma equipment
US20050136681A1 (en) * 2003-12-23 2005-06-23 Tokyo Electron Limited Method and apparatus for removing photoresist from a substrate
US20060000799A1 (en) * 2004-06-30 2006-01-05 Hyun-Ho Doh Methods and apparatus for determining endpoint in a plasma processing system
JP4972277B2 (en) * 2004-11-10 2012-07-11 東京エレクトロン株式会社 Substrate processing apparatus recovery method, apparatus recovery program, and substrate processing apparatus
US7624003B2 (en) * 2005-01-10 2009-11-24 Applied Materials, Inc. Split-phase chamber modeling for chamber matching and fault detection
US20080063810A1 (en) * 2006-08-23 2008-03-13 Applied Materials, Inc. In-situ process state monitoring of chamber
KR20160120382A (en) * 2015-04-07 2016-10-18 삼성전자주식회사 Apparatus for optical emission spectroscopy and apparatus for treating plasma
US10215704B2 (en) * 2017-03-02 2019-02-26 Tokyo Electron Limited Computed tomography using intersecting views of plasma using optical emission spectroscopy during plasma processing
US20200340858A1 (en) * 2019-04-24 2020-10-29 Applied Materials, Inc. Plasma emission monitoring system with cross-dispersion grating

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014055A1 (en) * 2000-04-07 2004-01-22 Daniel Birnbaum Gene coding for erbin, and diagnostic and therapeutic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03181129A (en) * 1989-12-11 1991-08-07 Sumitomo Metal Ind Ltd Method of detecting termination of etching
JP3169759B2 (en) * 1993-12-28 2001-05-28 株式会社日立製作所 Plasma etching method
JPH07263408A (en) * 1994-03-17 1995-10-13 Hitachi Ltd Plasma etching method
WO1999040617A1 (en) * 1998-02-03 1999-08-12 Tokyo Electron Yamanashi Limited End point detecting method for semiconductor plasma processing
JP4051470B2 (en) * 1999-05-18 2008-02-27 東京エレクトロン株式会社 End point detection method
JP3634734B2 (en) * 2000-09-22 2005-03-30 株式会社日立製作所 Plasma processing apparatus and processing method
JP2002110642A (en) * 2000-09-27 2002-04-12 Sharp Corp Plasma treatment method
US6783626B2 (en) * 2001-05-14 2004-08-31 Nam-Hun Kim Treatment and evaluation of a substrate processing chamber

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014055A1 (en) * 2000-04-07 2004-01-22 Daniel Birnbaum Gene coding for erbin, and diagnostic and therapeutic uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10692705B2 (en) 2015-11-16 2020-06-23 Tokyo Electron Limited Advanced optical sensor and method for detecting an optical event in a light emission signal in a plasma chamber
US10773282B2 (en) 2016-03-31 2020-09-15 Tokyo Electron Limited Controlling dry etch process characteristics using waferless dry clean optical emission spectroscopy
US11273469B2 (en) 2016-03-31 2022-03-15 Tokyo Electron Limited Controlling dry etch process characteristics using waferless dry clean optical emission spectroscopy
US10436717B2 (en) 2016-11-18 2019-10-08 Tokyo Electron Limited Compositional optical emission spectroscopy for detection of particle induced arcs in a fabrication process
US10446453B2 (en) 2017-03-17 2019-10-15 Tokyo Electron Limited Surface modification control for etch metric enhancement

Also Published As

Publication number Publication date
TWI280617B (en) 2007-05-01
WO2003103017A2 (en) 2003-12-11
US20040008336A1 (en) 2004-01-15
US6825920B2 (en) 2004-11-30
AU2003241474A1 (en) 2003-12-19
AU2003241474A8 (en) 2003-12-19
JP2005527984A (en) 2005-09-15
TW200406835A (en) 2004-05-01
WO2003103017A3 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
Santoro et al. Regulation of HCN channel surface expression by a novel C-terminal protein-protein interaction
Pante et al. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth
US20040058359A1 (en) Erbin as a negative regulator of Ras-Raf-Erk signaling
US7893203B2 (en) Protein involved in G protein-coupled receptor mediated signal transduction with ability to mediate signal transduction from a dopamine D1 receptor or an adenosine A2A receptor to an adenylate cyclase and utilization thereof
JP2000083669A (en) Human splicing variant cxcr4b of cxcr4 kemokine receptor
US7998491B2 (en) Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
US6184349B1 (en) Cloned peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit
JP2003530821A (en) Melanin-concentrating hormone receptor
WO2003102139A2 (en) Erbin as a negative regulator of ras-raf-erk signaling
Komatsuzaki et al. Modulation of Giα2 signaling by the axonal guidance molecule UNC5H2
US8546324B2 (en) Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
JP4583007B2 (en) Novel G-protein and use thereof
US7696339B2 (en) Nucleic acid encoding monkey QRFP
JP2009539362A (en) G protein-coupled receptor 39 (GPR39)
AU2004248913B2 (en) Proton-sensing G-protein coupled receptors and DNA sequences thereof
JP2003501079A (en) Gene encoding NADE (P75NTR-related cell death executive substance) and use thereof
WO2005093068A1 (en) Novel protein and promoter
JP2009060787A (en) Screening method and identification method for substance capable of inhibiting degranulation reaction in mast cell through rec168, and therapeutic agent for inflammatory disease concerned with mast cell containing rec168 antagonist
JP2005312364A (en) Method for screening therapeutic agent for diabetes mellitus
US20110059094A1 (en) Antitumor effects of insulin-responsive dna binding protein-1 (irdbp-1)
Yuan et al. Generation of mammalian cell lines with gene knock-down for human MCHR2
JP2003517008A (en) New compound
JP2006166703A (en) Cartilage differentiation regulating gene
JP2003507068A (en) G protein-coupled receptor expressed in brain

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE UAB RESEARCH FOUNDATION, ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEI, LIN;HUANG, YANGZHONG;XIONG, WEN C.;REEL/FRAME:018278/0656;SIGNING DATES FROM 20060831 TO 20060911

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION